1,261
Views
9
CrossRef citations to date
0
Altmetric
Hematology

Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption

, , , , , & show all
Pages 337-344 | Received 22 Sep 2016, Accepted 22 Nov 2016, Published online: 21 Dec 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Marijn van der Sluijs, Nicole Huyghe, Caroline Wood & Sally Tawil. (2022) A survey of physicians’ treatment switching practice in people on long-term prophylaxis for hemophilia in five European countries. Current Medical Research and Opinion 38:1, pages 65-73.
Read now
Joanna Davis, Songkai Yan, Tadashi Matsushita, Lorenzo Alberio, Paul Bassett & Elena Santagostino. (2019) Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP. Journal of Medical Economics 22:10, pages 1014-1021.
Read now
Giancarlo Castaman. (2018) The benefits of prophylaxis in patients with hemophilia B. Expert Review of Hematology 11:8, pages 673-683.
Read now

Articles from other publishers (6)

Daniel P. Hart, Davide Matino, Jan Astermark, Gerard Dolan, Roseline d’Oiron, Cédric Hermans, Victor Jiménez-Yuste, Adriana Linares, Tadashi Matsushita, Simon McRae, Margareth C. Ozelo, Sean Platton, Darrel Stafford, Robert F. SidonioJr.Jr. & Andreas Tiede. (2022) International consensus recommendations on the management of people with haemophilia B. Therapeutic Advances in Hematology 13, pages 204062072210852.
Crossref
Johnny N. Mahlangu, Victor Blanchette & Robert Klamroth. (2020) Redefining prophylaxis in the modern era. Haemophilia 27:S3, pages 21-27.
Crossref
RafalRaad Al-Janabi, AfrahA Salih & MohammedJ Alwan. (2021) Evaluation of efficacy of twice-weekly prophylactic treatment with BeneFIX® (recombinant factor IX) followed by once weekly in children with severe hemophilia B: Six-year data from a local registry. Iraqi Journal of Hematology 10:1, pages 59.
Crossref
Andrea Aiello, Maria Elisa Mancuso, Alessio Colombo, Cristina Teruzzi & Patrizia Berto. (2020) Budget impact analysis of extended half-life recombinant factor IX (rFIXFc) in the treatment of haemophilia B. Global & Regional Health Technology Assessment 7:1, pages 40-49.
Crossref
Johnny N. Mahlangu. (2018) Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors. BioDrugs 32:6, pages 561-570.
Crossref
G. F. Pierce & A. Iorio. (2018) Past, present and future of haemophilia gene therapy: From vectors and transgenes to known and unknown outcomes. Haemophilia 24, pages 60-67.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.